BBC Homepage World Service Education
BBC Homepagelow graphics version | feedback | help
BBC News Online
 You are in: Health
Front Page 
World 
UK 
UK Politics 
Business 
Sci/Tech 
Health 
Background Briefings 
Medical notes 
Education 
Entertainment 
Talking Point 
In Depth 
AudioVideo 

Tuesday, 1 August, 2000, 08:03 GMT 09:03 UK
Gene therapy cancer treatment success
pipette
The gene therapy has proved effective
A gene treatment injected directly into malignant tumours causes many to shrink, and some to disappear altogether.

The study, published in the journal Nature Medicine, is encouraging news for those who believe that these kinds of treatment could be used to target many different types of cancer.

In this case, 30 British and US patients suffering from head and neck cancer - which proves fatal in a third of cases - were treated with a modified common cold virus called ONYX-015.

This looked for a key genetic difference between cancer cells and healthy cells - in this case a relative deficiency of a gene called p53 - only destroying those lacking the gene.

This treatment was combined with standard chemotherapy, but the eventual results were better than those normally obtained by chemotherapy alone.

Tumours shrank in 25 out of 30 patients. In only 17% of the patients did the tumours progress.

In eight patients, the tumour disappeared completely - and had not returned by the time the trial reported.

This is an improvement over previous tests using only gene therapy, in which the tumours disappeared - but swiftly returned when treatment ended.

Gene mutation

Dr French Anderson, of the Gene Therapy Laboratories at the University of Southern California in Los Angeles, said that this was the first successful larger scale trial of a gene therapy.

He said: "ONYX-015 may be able to sensitise infected and uninfected cells to killing by chemotherapy."

It is thought that between 45% and 70% of head and neck tumour cells have mutations in the p53 gene, which normally helps the body repair damage that can lead to cancer.

There were side-effects, with some patients reporting flu-like symptoms, including fever, weakness and chills.

This treatment differs from many other gene therapies in that it does not seek to replace a damaged gene with a working copy in cells, but instead homes in on the deficient cell and works to destroy it.

Dr Mary Berrington, a science information officer at the Cancer Research Campaign, said that it seemed a "very promising" result.

She said: "This is an interesting approach to use the virus to kill the cell - one of the nice things about it is that it overcomes the problem of getting to every cancer cell - the virus simply does what it is good at and infects them."

Head and neck cancers are an obvious target for gene therapy, as their proximity to the skin surface makes it easier to inject the treatment directly into it.

To reach less accessible tumours - or treat cancers which could be anywhere in the body - much larger doses of the therapy would have to be given, or treatments tailored to seek out the cancer cells wherever they might be in the body.

Search BBC News Online

Advanced search options
Launch console
BBC RADIO NEWS
BBC ONE TV NEWS
WORLD NEWS SUMMARY
PROGRAMMES GUIDE
See also:

19 Mar 99 | Health
Gene fix for cystic fibrosis
18 May 99 | Health
'New era for cancer treatment'
03 Aug 99 | Health
Gene hope for hearts
Internet links:


The BBC is not responsible for the content of external internet sites

Links to more Health stories are at the foot of the page.


E-mail this story to a friend

Links to more Health stories